Sanofi's CER Deal with Medco's UBC Could Help ID Potential PGx Drugs in Pipeline

UBC's CER capabilities could help Sanofi opportunistically apply pharmacogenomic strategies in drug development and commercialize personalized medicines.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.